Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06454968
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-05-27
Brief Title:
Orelabrutinib Combined With Obinutuzumab and Lenalidomide OGL Regimen as First-line Treatment for Marginal Zone Lymphoma
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Organization Data
Organization:
Peking Union Medical College Hospital
Class:
OTHER
Study ID:
PUMCH-NHL-017
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking Union Medical College Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None